PROMUS PREMIER™ China Post-Approval Study
About the study
To compile real-world clinical outcome data for the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System (Promus PREMIERTM Stent System) in routine clinical practice in China.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Subject must be at least 18 years of age
- Subject understands and provides written informed consent
- Subject who is clinically indicated and will have an attempt of at least one Promus PREMIERTM Stent OR Subject who is clinically indicated and was implanted with at least one Promus PREMIERTM Stent
- Subject is willing to comply with all protocol-required follow-up evaluation
EXCLUSION CRITERIA
Exclusion Criteria:
Exclusion criteria are not required in the PE PREMIERTM China Post-Approval Study which is an "all comers" study.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Coronary Artery Disease
Age (in years)
18+
Participants needed
2059
Est. Completion Date
Sep 30, 2024
Treatment type
Observational [Patient Registry]
Sponsor
Boston Scientific Corporation
ClinicalTrials.gov identifier
NCT03273023
Study number
S2384
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?